Chi-Wai Ho1, Mei-Han Ho1, Pak-Hei Chan1, Jo-Jo Hai1, Emmanuel Cheung1, Chun-Yip Yeung1, Kui-Kai Lau1, Koon-Ho Chan1, Chu-Pak Lau1, Gregory Y H Lip1, Gilberto Ka-Kit Leung1, Hung-Fat Tse1, Chung-Wah Siu2. 1. From the Cardiology Division (C.-W.H., M.-H.H., P.-H.C., J.-J.H., E.C., C.-P.L., H.-F.T., C.-W.S.), Endocrinology Division (C.-Y.Y.), and Neurology Division (K.-K.L., K.-H.C.), Department of Medicine, Queen Mary Hospital and Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine (G.K.-K.L.), University of Hong Kong, Hong Kong SAR, China; and University of Birmingham Centre for Cardiovascular Sciences, City Hospital, University Department of Medicine, Birmingham, United Kingdom (G.Y.H.L.). 2. From the Cardiology Division (C.-W.H., M.-H.H., P.-H.C., J.-J.H., E.C., C.-P.L., H.-F.T., C.-W.S.), Endocrinology Division (C.-Y.Y.), and Neurology Division (K.-K.L., K.-H.C.), Department of Medicine, Queen Mary Hospital and Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine (G.K.-K.L.), University of Hong Kong, Hong Kong SAR, China; and University of Birmingham Centre for Cardiovascular Sciences, City Hospital, University Department of Medicine, Birmingham, United Kingdom (G.Y.H.L.). cwdsiu@hku.hk.
Abstract
BACKGROUND AND PURPOSE: Little is known about the impact of quality of anticoagulation control, as reflected by time in therapeutic range (TTR), on the effectiveness and safety of warfarin therapy in Chinese patients with atrial fibrillation. We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy. METHODS: This is an observational study. RESULTS: Of 8754 Chinese patients with atrial fibrillation and CHA2DS2-VASc ≥1 (79.5±9.2 years; CHA2DS2-VASc, 4.1±1.5; and Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly (>65 years), Drugs/Alcohol Concomitantly [HAS-BLED], 2.2±0.9), 16.3% received warfarin, 41.1% aspirin, 4.5% dabigatran, and 38.1% received no therapy. The incidence of ischemic stroke was highest in patients with no therapy (10.38%/y), followed by patients on aspirin (7.95%/y). The incidence of stroke decreased progressively with increasing TTR quartiles (<17.9%, 17.9%-38.8%, 38.8%-56.2%, and >56.2%) from 7.34%/y (first quartile) to 3.10%/y (fourth quartile). Patients on dabigatran had the lowest incidence of stroke among all groups (2.24%/y). The incidence of ICH was lowest in patients on dabigatran (0.32%/y) compared with those on warfarin (0.90%/y), aspirin (0.80%/y), and no therapy (0.53%/y). ICH incidence decreased with increasing TTR from 1.37%/y (first quartile) to 0.74%/y (fourth quartile). CONCLUSIONS: In Chinese patients with atrial fibrillation, the benefits of warfarin therapy for stroke prevention and ICH risk are closely dependent on the quality of anticoagulation, as reflected by TTR. Even at the top TTR quartile, warfarin was associated with a higher stroke and ICH risk than dabigatran.
BACKGROUND AND PURPOSE: Little is known about the impact of quality of anticoagulation control, as reflected by time in therapeutic range (TTR), on the effectiveness and safety of warfarin therapy in Chinese patients with atrial fibrillation. We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy. METHODS: This is an observational study. RESULTS: Of 8754 Chinese patients with atrial fibrillation and CHA2DS2-VASc ≥1 (79.5±9.2 years; CHA2DS2-VASc, 4.1±1.5; and Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly (>65 years), Drugs/Alcohol Concomitantly [HAS-BLED], 2.2±0.9), 16.3% received warfarin, 41.1% aspirin, 4.5% dabigatran, and 38.1% received no therapy. The incidence of ischemic stroke was highest in patients with no therapy (10.38%/y), followed by patients on aspirin (7.95%/y). The incidence of stroke decreased progressively with increasing TTR quartiles (<17.9%, 17.9%-38.8%, 38.8%-56.2%, and >56.2%) from 7.34%/y (first quartile) to 3.10%/y (fourth quartile). Patients on dabigatran had the lowest incidence of stroke among all groups (2.24%/y). The incidence of ICH was lowest in patients on dabigatran (0.32%/y) compared with those on warfarin (0.90%/y), aspirin (0.80%/y), and no therapy (0.53%/y). ICH incidence decreased with increasing TTR from 1.37%/y (first quartile) to 0.74%/y (fourth quartile). CONCLUSIONS: In Chinese patients with atrial fibrillation, the benefits of warfarin therapy for stroke prevention and ICH risk are closely dependent on the quality of anticoagulation, as reflected by TTR. Even at the top TTR quartile, warfarin was associated with a higher stroke and ICH risk than dabigatran.
Authors: Wen-Hua Li; Duo Huang; Chern-En Chiang; Chu-Pak Lau; Hung-Fat Tse; Esther W Chan; Ian C K Wong; Gregory Y H Lip; Pak-Hei Chan; Chung-Wah Siu Journal: Clin Cardiol Date: 2016-11-28 Impact factor: 2.882
Authors: Darae Ko; Faisal Rahman; Maria A P Martins; Elaine M Hylek; Patrick T Ellinor; Renate B Schnabel; Emelia J Benjamin; Ingrid E Christophersen Journal: Nat Rev Cardiol Date: 2016-10-27 Impact factor: 32.419
Authors: Pak Hei Chan; Jo Jo Hai; Esther W Chan; Wen Hua Li; Hung Fat Tse; Ian C K Wong; Gregory Y H Lip; Chung Wah Siu Journal: PLoS One Date: 2016-03-24 Impact factor: 3.240
Authors: Pak-Hei Chan; Jo-Jo Hai; Duo Huang; Mei-Han Ho; Esther W Chan; Bernard Man-Yung Cheung; Annie On-On Chan; Ian Chi-Kei Wong; Hung-Fat Tse; Ivan Fan-Ngai Hung; Chung-Wah Siu Journal: SAGE Open Med Date: 2016-08-04
Authors: Luis A García Rodríguez; Mar Martín-Pérez; Charles H Hennekens; Peter M Rothwell; Angel Lanas Journal: PLoS One Date: 2016-08-04 Impact factor: 3.240
Authors: Xue Li; Vicki C Tse; Wallis C Y Lau; Bernard M Y Cheung; Gregory Y H Lip; Ian C K Wong; Esther W Chan Journal: PLoS One Date: 2016-06-30 Impact factor: 3.240
Authors: Kueiyu Joshua Lin; Daniel E Singer; Robert J Glynn; Suzanne Blackley; Li Zhou; Jun Liu; Gina Dube; Lynn B Oertel; Sebastian Schneeweiss Journal: J Am Heart Assoc Date: 2017-10-05 Impact factor: 5.501